Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
Interest in performing dosimetry for clinical radiopharmaceutical therapy procedures has grown in recent years. Several approved therapies include dosimetry in the Food and Drug Administration-approved label instructions, and other therapies are best used under a patient-tailored paradigm. This pape...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2021-12, Vol.62 (Suppl 3), p.48S-59S |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59S |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | 48S |
| container_title | Journal of Nuclear Medicine |
| container_volume | 62 |
| creator | Graves, Stephen A Bageac, Alexandru Crowley, James R Merlino, Denise A M |
| description | Interest in performing dosimetry for clinical radiopharmaceutical therapy procedures has grown in recent years. Several approved therapies include dosimetry in the Food and Drug Administration-approved label instructions, and other therapies are best used under a patient-tailored paradigm. This paper, which is a product of the Society of Nuclear Medicine and Molecular Imaging Dosimetry Task Force, presents motivations and general workflows for radiopharmaceutical therapy dosimetry, as well as existing strategies for obtaining reimbursement for clinical activities related to dosimetry. Several specific patient examples are provided, including suggested codes for reimbursement. In addition to current reimbursement approaches, key dosimetry services that are not supported under the current coding structure are presented and suggested as areas of focus in the coming years. |
| doi_str_mv | 10.2967/jnumed.121.262752 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2606923144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2607324392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-b0aae8ae6eaaaf39152a40d724865f5101dc25e47b3caa140a84c65d0f054dff3</originalsourceid><addsrcrecordid>eNpdkctKw1AQhg-i2Fp9ADcScOMm9dyTuivVqlAoVF2HycmEpuTmuSz69qa03biaxXz_MDMfIfeMTvlMJ8-7NjRYTBlnU655ovgFGTMlVKy0Ti7JmDLNYqWoGpEb53aUUp2m6TUZCZmqRHM-JmaDVZMH67DB1kfzvrcdmC26qOxstIGi6vot2AYMBl8ZqKPXzlUNert_iRbB2kPqy4MPLoK2iJbBB4vRuu8760Nb-QrdLbkqoXZ4d6oT8rN8-158xKv1--divoqNSLiPcwqAKaBGACjFjCkOkhYJl6lWpWKUFYYrlEkuDACTFFJptCpoSZUsylJMyNNx7nDDb0Dns6ZyBusaWuyCy7imesYFk3JAH_-huy7YdtjuQCWCSzGQE8KOlLGdcxbLrLdVA3afMZodDGRHA9lgIDsaGDIPp8khP7TOifPLxR-s4YTI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607324392</pqid></control><display><type>article</type><title>Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Graves, Stephen A ; Bageac, Alexandru ; Crowley, James R ; Merlino, Denise A M</creator><creatorcontrib>Graves, Stephen A ; Bageac, Alexandru ; Crowley, James R ; Merlino, Denise A M</creatorcontrib><description>Interest in performing dosimetry for clinical radiopharmaceutical therapy procedures has grown in recent years. Several approved therapies include dosimetry in the Food and Drug Administration-approved label instructions, and other therapies are best used under a patient-tailored paradigm. This paper, which is a product of the Society of Nuclear Medicine and Molecular Imaging Dosimetry Task Force, presents motivations and general workflows for radiopharmaceutical therapy dosimetry, as well as existing strategies for obtaining reimbursement for clinical activities related to dosimetry. Several specific patient examples are provided, including suggested codes for reimbursement. In addition to current reimbursement approaches, key dosimetry services that are not supported under the current coding structure are presented and suggested as areas of focus in the coming years.</description><identifier>ISSN: 0161-5505</identifier><identifier>ISSN: 1535-5667</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.121.262752</identifier><identifier>PMID: 34857622</identifier><language>eng</language><publisher>United States: Society of Nuclear Medicine</publisher><subject>Dosimeters ; Dosimetry ; FDA approval ; Humans ; Nuclear medicine ; Nuclear Medicine - economics ; Patients ; Pharmaceuticals ; Radiochemistry ; Radioisotopes ; Radiometry - economics ; Radiopharmaceuticals - economics ; Radiopharmaceuticals - therapeutic use ; Reimbursement ; Reimbursement Mechanisms ; United States ; United States Food and Drug Administration</subject><ispartof>Journal of Nuclear Medicine, 2021-12, Vol.62 (Suppl 3), p.48S-59S</ispartof><rights>2021 by the Society of Nuclear Medicine and Molecular Imaging.</rights><rights>Copyright Society of Nuclear Medicine Dec 1, 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-b0aae8ae6eaaaf39152a40d724865f5101dc25e47b3caa140a84c65d0f054dff3</citedby><cites>FETCH-LOGICAL-c372t-b0aae8ae6eaaaf39152a40d724865f5101dc25e47b3caa140a84c65d0f054dff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34857622$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Graves, Stephen A</creatorcontrib><creatorcontrib>Bageac, Alexandru</creatorcontrib><creatorcontrib>Crowley, James R</creatorcontrib><creatorcontrib>Merlino, Denise A M</creatorcontrib><title>Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>Interest in performing dosimetry for clinical radiopharmaceutical therapy procedures has grown in recent years. Several approved therapies include dosimetry in the Food and Drug Administration-approved label instructions, and other therapies are best used under a patient-tailored paradigm. This paper, which is a product of the Society of Nuclear Medicine and Molecular Imaging Dosimetry Task Force, presents motivations and general workflows for radiopharmaceutical therapy dosimetry, as well as existing strategies for obtaining reimbursement for clinical activities related to dosimetry. Several specific patient examples are provided, including suggested codes for reimbursement. In addition to current reimbursement approaches, key dosimetry services that are not supported under the current coding structure are presented and suggested as areas of focus in the coming years.</description><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Nuclear medicine</subject><subject>Nuclear Medicine - economics</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Radiochemistry</subject><subject>Radioisotopes</subject><subject>Radiometry - economics</subject><subject>Radiopharmaceuticals - economics</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Reimbursement</subject><subject>Reimbursement Mechanisms</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctKw1AQhg-i2Fp9ADcScOMm9dyTuivVqlAoVF2HycmEpuTmuSz69qa03biaxXz_MDMfIfeMTvlMJ8-7NjRYTBlnU655ovgFGTMlVKy0Ti7JmDLNYqWoGpEb53aUUp2m6TUZCZmqRHM-JmaDVZMH67DB1kfzvrcdmC26qOxstIGi6vot2AYMBl8ZqKPXzlUNert_iRbB2kPqy4MPLoK2iJbBB4vRuu8760Nb-QrdLbkqoXZ4d6oT8rN8-158xKv1--divoqNSLiPcwqAKaBGACjFjCkOkhYJl6lWpWKUFYYrlEkuDACTFFJptCpoSZUsylJMyNNx7nDDb0Dns6ZyBusaWuyCy7imesYFk3JAH_-huy7YdtjuQCWCSzGQE8KOlLGdcxbLrLdVA3afMZodDGRHA9lgIDsaGDIPp8khP7TOifPLxR-s4YTI</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Graves, Stephen A</creator><creator>Bageac, Alexandru</creator><creator>Crowley, James R</creator><creator>Merlino, Denise A M</creator><general>Society of Nuclear Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities</title><author>Graves, Stephen A ; Bageac, Alexandru ; Crowley, James R ; Merlino, Denise A M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-b0aae8ae6eaaaf39152a40d724865f5101dc25e47b3caa140a84c65d0f054dff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Nuclear medicine</topic><topic>Nuclear Medicine - economics</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Radiochemistry</topic><topic>Radioisotopes</topic><topic>Radiometry - economics</topic><topic>Radiopharmaceuticals - economics</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Reimbursement</topic><topic>Reimbursement Mechanisms</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Graves, Stephen A</creatorcontrib><creatorcontrib>Bageac, Alexandru</creatorcontrib><creatorcontrib>Crowley, James R</creatorcontrib><creatorcontrib>Merlino, Denise A M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Graves, Stephen A</au><au>Bageac, Alexandru</au><au>Crowley, James R</au><au>Merlino, Denise A M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2021-12</date><risdate>2021</risdate><volume>62</volume><issue>Suppl 3</issue><spage>48S</spage><epage>59S</epage><pages>48S-59S</pages><issn>0161-5505</issn><issn>1535-5667</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>Interest in performing dosimetry for clinical radiopharmaceutical therapy procedures has grown in recent years. Several approved therapies include dosimetry in the Food and Drug Administration-approved label instructions, and other therapies are best used under a patient-tailored paradigm. This paper, which is a product of the Society of Nuclear Medicine and Molecular Imaging Dosimetry Task Force, presents motivations and general workflows for radiopharmaceutical therapy dosimetry, as well as existing strategies for obtaining reimbursement for clinical activities related to dosimetry. Several specific patient examples are provided, including suggested codes for reimbursement. In addition to current reimbursement approaches, key dosimetry services that are not supported under the current coding structure are presented and suggested as areas of focus in the coming years.</abstract><cop>United States</cop><pub>Society of Nuclear Medicine</pub><pmid>34857622</pmid><doi>10.2967/jnumed.121.262752</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2021-12, Vol.62 (Suppl 3), p.48S-59S |
| issn | 0161-5505 1535-5667 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2606923144 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Dosimeters Dosimetry FDA approval Humans Nuclear medicine Nuclear Medicine - economics Patients Pharmaceuticals Radiochemistry Radioisotopes Radiometry - economics Radiopharmaceuticals - economics Radiopharmaceuticals - therapeutic use Reimbursement Reimbursement Mechanisms United States United States Food and Drug Administration |
| title | Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A49%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reimbursement%20Approaches%20for%20Radiopharmaceutical%20Dosimetry:%20Current%20Status%20and%20Future%20Opportunities&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Graves,%20Stephen%20A&rft.date=2021-12&rft.volume=62&rft.issue=Suppl%203&rft.spage=48S&rft.epage=59S&rft.pages=48S-59S&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.121.262752&rft_dat=%3Cproquest_cross%3E2607324392%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607324392&rft_id=info:pmid/34857622&rfr_iscdi=true |